Login / Signup

Efficacy of elafibranor in patients with liver abnormalities especially non-alcoholic steatohepatitis: a systematic review and meta-analysis.

Adnan MalikMahum NadeemMuhammad Imran Malik
Published in: Clinical journal of gastroenterology (2021)
PPAR-alpha/delta dual agonist, elafibranor, is a promising drug that improves most metabolic parameters in dyslipidemic patients.
Keyphrases
  • end stage renal disease
  • newly diagnosed
  • ejection fraction
  • chronic kidney disease
  • prognostic factors
  • insulin resistance
  • patient reported outcomes
  • fatty acid
  • liver fibrosis